Literature DB >> 24852293

Mutations in SETD2 cause a novel overgrowth condition.

Armelle Luscan1, Ingrid Laurendeau1, Valérie Malan2, Christine Francannet3, Sylvie Odent4, Fabienne Giuliano5, Didier Lacombe6, Renaud Touraine7, Michel Vidaud1, Eric Pasmant1, Valérie Cormier-Daire8.   

Abstract

BACKGROUND: Overgrowth conditions are a heterogeneous group of disorders characterised by increased growth and variable features, including macrocephaly, distinctive facial appearance and various degrees of learning difficulties and intellectual disability. Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively. NSD1 and EZH2 are both histone-modifying enzymes. These two epigenetic writers catalyse two specific post-translational modifications of histones: methylation of histone 3 lysine 36 (H3K36) and lysine 27 (H3K27). We postulated that mutations in writers of these two chromatin marks could cause overgrowth conditions, resembling Sotos or Weaver syndromes, in patients with no NSD1 or EZH2 abnormalities.
METHODS: We analysed the coding sequences of 14 H3K27 methylation-related genes and eight H3K36 methylation-related genes using a targeted next-generation sequencing approach in three Sotos, 11 'Sotos-like' and two Weaver syndrome patients.
RESULTS: We identified two heterozygous mutations in the SETD2 gene in two patients with 'Sotos-like' syndrome: one missense p.Leu1815Trp de novo mutation in a boy and one nonsense p.Gln274* mutation in an adopted girl. SETD2 is non-redundantly responsible for H3K36 trimethylation. The two probands shared similar clinical features, including postnatal overgrowth, macrocephaly, obesity, speech delay and advanced carpal ossification.
CONCLUSIONS: Our results illustrate the power of targeted next-generation sequencing to identify rare disease-causing variants. We provide a compelling argument for Sotos and Sotos-like syndromes as epigenetic diseases caused by loss-of-function mutations of epigenetic writers of the H3K36 histone mark. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Clinical genetics; Developmental; Molecular genetics

Mesh:

Substances:

Year:  2014        PMID: 24852293     DOI: 10.1136/jmedgenet-2014-102402

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  37 in total

Review 1.  SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.

Authors:  Catherine C Fahey; Ian J Davis
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

2.  Delineation of a Human Mendelian Disorder of the DNA Demethylation Machinery: TET3 Deficiency.

Authors:  David B Beck; Ana Petracovici; Chongsheng He; Hannah W Moore; Raymond J Louie; Muhammad Ansar; Sofia Douzgou; Sivagamy Sithambaram; Trudie Cottrell; Regie Lyn P Santos-Cortez; Eloise J Prijoles; Renee Bend; Boris Keren; Cyril Mignot; Marie-Christine Nougues; Katrin Õunap; Tiia Reimand; Sander Pajusalu; Muhammad Zahid; Muhammad Arif Nadeem Saqib; Julien Buratti; Eleanor G Seaby; Kirsty McWalter; Aida Telegrafi; Dustin Baldridge; Marwan Shinawi; Suzanne M Leal; G Bradley Schaefer; Roger E Stevenson; Siddharth Banka; Roberto Bonasio; Jill A Fahrner
Journal:  Am J Hum Genet       Date:  2020-01-09       Impact factor: 11.025

Review 3.  Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability.

Authors:  Stefan H Lelieveld; Margot R F Reijnders; Rolph Pfundt; Helger G Yntema; Erik-Jan Kamsteeg; Petra de Vries; Bert B A de Vries; Marjolein H Willemsen; Tjitske Kleefstra; Katharina Löhner; Maaike Vreeburg; Servi J C Stevens; Ineke van der Burgt; Ernie M H F Bongers; Alexander P A Stegmann; Patrick Rump; Tuula Rinne; Marcel R Nelen; Joris A Veltman; Lisenka E L M Vissers; Han G Brunner; Christian Gilissen
Journal:  Nat Neurosci       Date:  2016-08-01       Impact factor: 24.884

Review 4.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

5.  A novel mutation in EED associated with overgrowth.

Authors:  Ana S A Cohen; Beyhan Tuysuz; Yaoqing Shen; Sanjiv K Bhalla; Steven J M Jones; William T Gibson
Journal:  J Hum Genet       Date:  2015-03-19       Impact factor: 3.172

Review 6.  A Clinical Review of Generalized Overgrowth Syndromes in the Era of Massively Parallel Sequencing.

Authors:  Benjamin Kamien; Anne Ronan; Gemma Poke; Ingrid Sinnerbrink; Gareth Baynam; Michelle Ward; William T Gibson; Tracy Dudding-Byth; Rodney J Scott
Journal:  Mol Syndromol       Date:  2018-01-25

7.  Genome-wide Enrichment of De Novo Coding Mutations in Orofacial Cleft Trios.

Authors:  Madison R Bishop; Kimberly K Diaz Perez; Miranda Sun; Samantha Ho; Pankaj Chopra; Nandita Mukhopadhyay; Jacqueline B Hetmanski; Margaret A Taub; Lina M Moreno-Uribe; Luz Consuelo Valencia-Ramirez; Claudia P Restrepo Muñeton; George Wehby; Jacqueline T Hecht; Frederic Deleyiannis; Seth M Weinberg; Yah Huei Wu-Chou; Philip K Chen; Harrison Brand; Michael P Epstein; Ingo Ruczinski; Jeffrey C Murray; Terri H Beaty; Eleanor Feingold; Robert J Lipinski; David J Cutler; Mary L Marazita; Elizabeth J Leslie
Journal:  Am J Hum Genet       Date:  2020-06-22       Impact factor: 11.025

Review 8.  Epigenetic Mistakes in Neurodevelopmental Disorders.

Authors:  Giuseppina Mastrototaro; Mattia Zaghi; Alessandro Sessa
Journal:  J Mol Neurosci       Date:  2017-03-02       Impact factor: 3.444

9.  A New Case of an Extremely Rare 3p21.31 Interstitial Deletion.

Authors:  Luca Lovrecic; Sara Bertok; Mojca Žerjav Tanšek
Journal:  Mol Syndromol       Date:  2016-04-19

Review 10.  Histone lysine methyltransferases in biology and disease.

Authors:  Dylan Husmann; Or Gozani
Journal:  Nat Struct Mol Biol       Date:  2019-10-03       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.